Zobrazeno 1 - 10
of 108
pro vyhledávání: '"Yuan-Hung Kuo"'
Autor:
Ya‐Wen Hsiao, Fai‐Meng Sou, Jing‐Houng Wang, Yen‐Hao Chen, Ming‐Chao Tsai, Tsung‐Hui Hu, Chao‐Hung Hung, Chien‐Hung Chen, Yuan‐Hung Kuo
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 39, Iss 12, Pp 1233-1242 (2023)
Abstract Lenvatinib has been approved as one of the first‐line treatments for advanced hepatocellular carcinoma (HCC) due to its high treatment efficacy being non‐inferior to sorafenib. Previous studies have shown well‐controlled viremia contri
Externí odkaz:
https://doaj.org/article/b1252245566d40eeb3fd8e2ddd0e4a28
Autor:
Wei-Ru Cho, Chih-Chi Wang, Mu-Jung Tsai, Chih-Che Lin, Yi-Hao Yen, Chien Hung Chen, Yuan-Hung Kuo, Chih-Chien Yao, Chao-Hung Hung, Pao-Yuan Huang, An-Che Liu, Ming-Chao Tsai
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 18 (2024)
Background: The risk of first recurrence of hepatocellular carcinoma (HCC) within years 5 to 10 after curative hepatectomy remains unknown. We aimed to assess the incidence and prognostic factors for very late recurrence among patients who achieved 5
Externí odkaz:
https://doaj.org/article/bbb17fa5e8f546c48bec8f2975145a64
Autor:
Shih-Yu Yang, Tsung-Hui Hu, Yeh-Pin Chou, Yuan-Hung Kuo, Ming-Chao Tsai, Kuo-Chin Chang, Yi-Hao Yen, Po-Lin Tseng
Publikováno v:
Journal of Infection and Public Health, Vol 16, Iss 11, Pp 1852-1859 (2023)
Background: Prophylaxis antiviral therapy is recommended for patients with hepatitis B receiving chemotherapy but the ideal treatment duration after chemotherapy cessation needs more evidence for clarification. Aims: This study aimed to compare the r
Externí odkaz:
https://doaj.org/article/2b55cf6c24544b049bd644f0f356897a
Autor:
Yen-Hao Chen, Ching-Hua Tsai, Yen-Yang Chen, Chih-Chi Wang, Jing-Houng Wang, Chao-Hung Hung, Yuan-Hung Kuo
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Nivolumab and pembrolizumab have not been directly compared in clinical trials, and the aim of this study is to investigate the efficacy and safety of nivolumab versus pembrolizumab in patients with advanced hepatocellular carcino
Externí odkaz:
https://doaj.org/article/4968e9b4155e4e21abbd173f7d0859eb
Autor:
Yi-Hao Yen, Kwong-Ming Kee, Tsung-Hui Hu, Ming-Chao Tsai, Yuan-Hung Kuo, Wei-Feng Li, Yueh-Wei Liu, Chih-Chi Wang, Chih-Yun Lin
Publikováno v:
PLoS ONE, Vol 19, Iss 3, p e0290523 (2024)
BackgroundWhether the etiology of chronic liver disease (CLD) impacts the overall survival (OS) of patients with hepatocellular carcinoma (HCC) remains unclear. We aim to clarify this issue.Materials and methodsBetween 2011 and 2020, 3941 patients wh
Externí odkaz:
https://doaj.org/article/4f15f10721dc46be9b6cafc213ae8dd0
Autor:
Wei-Chen Tai, Shih-Cheng Yang, Chih-Chien Yao, Cheng-Kun Wu, An-Che Liu, Chen-Hsiang Lee, Yuan-Hung Kuo, Seng-Kee Chuah, Chih-Ming Liang
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 5, Pp 1415-1427 (2023)
Abstract Introduction High-dose dual therapy (HDDT) can attain acceptable eradication rates provided that the optimal doses, timing and treatment duration are applied. The existing evidence still shows inconsistent reports ( 90% eradication rates for
Externí odkaz:
https://doaj.org/article/13c47a02e8df4799a7631184a8026807
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background The approved dose of nivolumab is 3 mg/kg or a flat dose of 240 mg for indications. There is no dose-response relationship for nivolumab; therefore, a low-dose regimen may be an option to reduce financial toxicity. This study was
Externí odkaz:
https://doaj.org/article/3582882d69f245ae8e833de29eb529ff
Autor:
Hsin-Yeh Chen, Kwong-Ming Kee, Sheng-Nan Lu, Jing-Houng Wang, Chien-Hung Chen, Chao-Hung Hung, Yi-Hao Yen, Yuan-Hung Kuo
Publikováno v:
Journal of the Formosan Medical Association, Vol 121, Iss 4, Pp 778-786 (2022)
Background/Purpose: This study is to use albumin-bilirubin (ALBI) grade and up-to-7 (UT7) criteria to assess outcomes of patients with intermediate stage hepatocellular carcinoma (HCC) after transarterial (chemo)embolization (TA(C)E). Methods: Betwee
Externí odkaz:
https://doaj.org/article/d5b5b3072c454caabf585f5f5407a86f
Autor:
Yuan‐Hung Kuo, Kwong‐Ming Kee, Chao‐Hung Hung, Sheng‐Nan Lu, Tsung‐Hui Hu, Chien‐Hung Chen, Jing‐Houng Wang
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 38, Iss 3, Pp 268-276 (2022)
Abstract To determine whether liver stiffness (LS) and fibrosis‐4 (Fib‐4) index were useful in assessing the occurrence of liver‐related complications (LRC) in chronic hepatitis C (CHC) patients after direct‐acting antivirals (DAAs) had been
Externí odkaz:
https://doaj.org/article/caebe628fecc4442af7c37246ce46d83
Autor:
Yu‐Chi Lee, Jing‐Houng Wang, Chien‐Hung Chen, Chao‐Hung Hung, Kai‐Che Lo, Yi‐Hao Yen, Kwong‐Ming Kee, Tsung‐Hui Hu, Sheng‐Nan Lu, Yuan‐Hung Kuo
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 37, Iss 10, Pp 894-902 (2021)
Abstract Sorafenib is the recommended first‐line treatment option for patients with advanced hepatocellular carcinoma (HCC). Hepatitis C virus (HCV)‐related advanced HCC (HCV–HCC) seemed to have a better response than hepatitis B virus (HBV)‐
Externí odkaz:
https://doaj.org/article/87b66098d711463aaad12c7061fa069e